Sep 17, 10:05 AMT. Rowe Price Biotech ETF (TDNA) began trading on Nasdaq today as a new fully transparent, actively managed biotech fund with an expense ratio of 0.55%.
Actively managed ETF that invests at least 80% of net assets in biotechnology companies engaged in healthcare innovation, primarily U.S. common stocks of any market capitalization, using fundamental bottom-up analysis with a focus on new platform technologies and novel therapeutic approaches. Seeks long-term capital appreciation.
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, alerts, and much more.